Verisante Aura is Named a 2013 Bronze Edison Award Winner

Verisante Aura is Named a 2013 Bronze Edison Award Winner 
REVOLUTIONARY SKIN CANCER DETECTOR HONOURED IN CHICAGO 
VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 04/26/13 -- Verisante
Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF)(FRANKFURT:V3T) (the
"Company" or "Verisante"), a leader in cancer detection technology,
announced today that Verisante Aura(TM), a non-invasive skin cancer
detection device, was voted a Bronze Edison Award winner for
innovation at the April 25th event at Navy Pier in Chicago.  
"Our judges recognized Aura(TM) as a true innovator out of the many
products in its category," said Frank Bonafilia, executive director
of the Edison Awards. 
Being recognized with an Edison Award has become one of the highest
accolades a company can receive in the name of innovation and
business. The awards are named after Thomas Alva Edison (1847-1931)
whose inventions, new product development methods and innovative
achievements literally changed the world, garnered him 1,093 U.S.
patents, and made him a household name around the world.  
"We are humbled and honoured to win the Edison Award," said Thomas
Braun, President & CEO, Verisante Technology, Inc., who joined
hundreds of senior executives from some of the world's most
recognized companies to accept the award. "This is the first time
that we have an objective tool that provides a scientific measurement
of a lesion to help dermatologists make a biopsy decision. None of
this would be possible without the tireless efforts of our scientists
and staff who pioneered a better way to diagnose skin cancer for
significantly improved patient outcomes."  
The clinical study results of Aura(TM) were published last year in
the peer-reviewed journal, Cancer Research and showed that the device
provides a significant advancement over current clinical diagnosis.
The study results showed that Aura(TM) had a success rate of 99 per
cent in finding skin cancer and the potential to reduce unnecessary
biopsies by 50 to 100 per cent.  
The ballot of nominees for the Edison Awards(TM) was judged by a
panel of more than 3,000 leading business executives including past
award winners, academics and leaders in the fields of product
development, design, engineering, science and medical. One of the
evening's many 
highlights was the presentation of the prestigious
Edison Achievement Award to Dr. Paul E. Jacobs, chairman and CEO of
Qualcomm Incorporated. The award honors innovation leaders and
business executives who have made a significant and lasting
contribution to innovation throughout their careers. The Edison
Achievement Award serves as inspiration to future innovators and to
the world at large. 
In addition to the Awards Gala, the annual Edison Awards program
encompassed multiple events over a two-day period including an
opening reception, "Meet the Innovators Forum" and the "Innovators'
Showcase", which offered guests a hands-on experience with many of
the winning products. 
About the Edison Awards(TM) 
The Edison Awards is a program conducted by Edison Universe, a
non-profit, 501(c)(3) organization dedicated to fostering future
innovators. The Awards have been recognizing and honoring the best in
innovations and innovators since 1987. They honor game-changing
innovations that are at the forefront of new product and service
development, marketing and human-centered design, and are one of the
highest accolades a company can receive in the name of successful
innovation. For more information about the Edison Awards complete
program and a list of past winners, visit www.edisonawards.com. 
About Verisante Technology, Inc. 
Verisante is a medical device company committed to commercializing
innovative systems for the early detection of cancer. The Verisante
Aura(TM) for skin cancer detection and the Verisante Core(TM) series
for lung, colon and cervical cancer detection utilize a proprietary
cancer detection platform while the operating software and probe
technology are unique to each device. The cancer detection platform
was developed by the BC Cancer Agency and tested and refined at the
Skin Care Centre at Vancouver General Hospital. This exclusive
platform technology allows Verisante to develop and offer a range of
compact, non-invasive cancer detection devices that offer physicians
immediate results for many of the most common cancers. Aura(TM) has
been approved for sale in Canada, Europe and Australia. The Core(TM)
has not yet been approved for sale.  
Verisante Aura(TM) was awarded Popular Science Magazine's "Best of
What's New Award" for 2011, and awarded a 2013 Prism Award for
Innovation in Photonics. Verisante Core(TM) was named one of the top
10 cancer breakthroughs of 2011 by the Canadian Cancer Society.  
Forward-Looking Statements  
This release contains forward-looking statements, including, but not
limited to, statements regarding the future commercialization of
medical devices, the market demand for these products and the
proprietary protections the Company will obtain with regard to the
technology, all of which statements are subject to market risks, and
the possibility that the Company will not be able to obtain patent
protection or obtain sufficient customer demand. These statements are
made based upon current expectations and actual results may differ
from those projected due to a number of risks and uncertainties. 
The TSX Venture Exchange has neither approved nor disapproved of the
contents of this press release. Neither the TSX Venture Exchange nor
its Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for the
adequacy or accuracy of this press release. 
Contacts:
Verisante Technology, Inc.
Thomas Braun
President & CEO
(604) 605-0507
info@verisante.com
www.verisante.com 
YouTube: www.youtube.com/verisante
Twitter: www.twitter.com/verisante
Facebook: www.facebook.com/verisante